WO2021207082A3 - Method for treating implantable device infections - Google Patents

Method for treating implantable device infections Download PDF

Info

Publication number
WO2021207082A3
WO2021207082A3 PCT/US2021/025794 US2021025794W WO2021207082A3 WO 2021207082 A3 WO2021207082 A3 WO 2021207082A3 US 2021025794 W US2021025794 W US 2021025794W WO 2021207082 A3 WO2021207082 A3 WO 2021207082A3
Authority
WO
WIPO (PCT)
Prior art keywords
implantable device
treating
device infections
treating implantable
phage
Prior art date
Application number
PCT/US2021/025794
Other languages
French (fr)
Other versions
WO2021207082A2 (en
Inventor
Subhendu BASU
Robert Hopkins
Greg Merril
Joseph FACKLER
Original Assignee
Adaptive Phage Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptive Phage Therapeutics, Inc. filed Critical Adaptive Phage Therapeutics, Inc.
Priority to CA3174729A priority Critical patent/CA3174729A1/en
Priority to CN202180032803.3A priority patent/CN116096390A/en
Priority to EP21723463.2A priority patent/EP4132552A2/en
Priority to JP2022560902A priority patent/JP2023520583A/en
Publication of WO2021207082A2 publication Critical patent/WO2021207082A2/en
Publication of WO2021207082A3 publication Critical patent/WO2021207082A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/14—Streptococcus; Staphylococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the field of phage therapy and is particularly directed at providing a phage-based composition and method for treating or preventing infections associated with implantable devices. The composition may be directly administered to the infected location of the device, optionally as a single dose, and/or by other modes of administrations, and may potentially avoid any requirement for replacing the implantable device.
PCT/US2021/025794 2020-04-06 2021-04-05 Method for treating implantable device infections WO2021207082A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA3174729A CA3174729A1 (en) 2020-04-06 2021-04-05 Method for treating implantable device infections
CN202180032803.3A CN116096390A (en) 2020-04-06 2021-04-05 Methods of treating implantable device infections
EP21723463.2A EP4132552A2 (en) 2020-04-06 2021-04-05 Method for treating implantable device infections
JP2022560902A JP2023520583A (en) 2020-04-06 2021-04-05 Methods for treating implantable device infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063005878P 2020-04-06 2020-04-06
US63/005,878 2020-04-06
US202063039475P 2020-06-16 2020-06-16
US63/039,475 2020-06-16

Publications (2)

Publication Number Publication Date
WO2021207082A2 WO2021207082A2 (en) 2021-10-14
WO2021207082A3 true WO2021207082A3 (en) 2021-12-02

Family

ID=75787211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025794 WO2021207082A2 (en) 2020-04-06 2021-04-05 Method for treating implantable device infections

Country Status (5)

Country Link
EP (1) EP4132552A2 (en)
JP (1) JP2023520583A (en)
CN (1) CN116096390A (en)
CA (1) CA3174729A1 (en)
WO (1) WO2021207082A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035303A2 (en) * 2007-09-13 2009-03-19 Intron Biotechnology, Inc. Bacteriophage or lytic protein derived from the bacteriophage which effective for treatment of staphylococcus aureus biofilm
US20120276054A1 (en) * 2011-04-28 2012-11-01 Williams Henry N Alternative bacterial treatment
WO2017015652A1 (en) * 2015-07-23 2017-01-26 Enbiotix, Inc. Bacteriophage for treating staphylococcus infections
WO2018126108A1 (en) * 2016-12-29 2018-07-05 Enbiotix, Inc. Bacteriophage having modified recognition baseplate protein structural domains
EP3372085A1 (en) * 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
WO2019136109A1 (en) * 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Therapeutics bacteriophage compositions for treating staphylococcus infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035303A2 (en) * 2007-09-13 2009-03-19 Intron Biotechnology, Inc. Bacteriophage or lytic protein derived from the bacteriophage which effective for treatment of staphylococcus aureus biofilm
US20120276054A1 (en) * 2011-04-28 2012-11-01 Williams Henry N Alternative bacterial treatment
WO2017015652A1 (en) * 2015-07-23 2017-01-26 Enbiotix, Inc. Bacteriophage for treating staphylococcus infections
WO2018126108A1 (en) * 2016-12-29 2018-07-05 Enbiotix, Inc. Bacteriophage having modified recognition baseplate protein structural domains
EP3372085A1 (en) * 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
WO2019136109A1 (en) * 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Therapeutics bacteriophage compositions for treating staphylococcus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASLAM S ET AL: "Novel Bacteriophage Therapy for Treatment of Ventricular Assist Device Infections", JOURNAL OF HEART AND LUNG TRANSPLANTATION, vol. 38, no. 4, April 2019 (2019-04-01) - April 2019 (2019-04-01), XP085631251, ISSN: 1053-2498, DOI: 10.1016/J.HEALUN.2019.01.542 *
VYBIRAL D ET AL: "Complete nucleotide sequence and molecular characterization of two lytic Staphylococcus aureus phages: 44AHJD and P68", FEMS MICROBIOLOGY LETTERS, NO LONGER PUBLISHED BY ELSEVIER, vol. 219, no. 2, 28 February 2003 (2003-02-28), pages 275 - 283, XP002294686, ISSN: 0378-1097, DOI: 10.1016/S0378-1097(03)00028-4 *

Also Published As

Publication number Publication date
CN116096390A (en) 2023-05-09
WO2021207082A2 (en) 2021-10-14
CA3174729A1 (en) 2021-10-14
EP4132552A2 (en) 2023-02-15
JP2023520583A (en) 2023-05-17

Similar Documents

Publication Publication Date Title
AU2018238202A8 (en) Combination therapy for the treatment or prevention of tumours
NZ751197A (en) Compounds and methods of treating infections
PH12020550107A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
WO2012106264A3 (en) Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
MX2018004309A (en) Combination therapies for treating cancer.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2016011682A (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics.
WO2020076760A3 (en) Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection
MX2020010697A (en) Kit, composition and combination therapy for fragile x syndrome.
MX2022005624A (en) Treatment of vomiting and nausea with minimum dose of olanzapine.
PH12018500202A1 (en) New effective aminoglycoside antibiotic for multidrug-resistant
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
EA202190171A1 (en) THE APPLICATION OF CONFIDENTIAL SPECIES FOR THE TREATMENT OF ATOPIC DERMATITIS
MX2021015673A (en) Biofilm disruption.
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
MX2021010884A (en) Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a complication risk factor.
WO2021207082A3 (en) Method for treating implantable device infections
MX2023011203A (en) Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder.
WO2023122260A3 (en) Inhibitors of sars-cov-2
MX2019004879A (en) Materials and methods for the control of biofilm.
BR112021018219A2 (en) Method of treatment of infective endocarditis
MX2023003350A (en) Treatment of vomiting and nausea with minimum dose of olanzapine.
BR112022010473A2 (en) ANTIBACTERIAL TREATMENT USING A CANABINOID AND AN ACTIVE AGENT
BR112021025306A2 (en) Drug and its use for the treatment of bacterial infections involving biofilm
MX2021004138A (en) Methods and formulations for treating chemotherapy-induced nausea and vomiting.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21723463

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2022560902

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3174729

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021723463

Country of ref document: EP

Effective date: 20221107